The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968 on ClinicalTrials.gov · last registry update 2011-06-30
A small phase 2/phase 3 — 8 participants, against a typical 60. The sponsor logged completion for November 2010. Primary outcome, as filed: steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University of Aarhus
- Sponsor type
- Other
- Enrollment
- 8
- Started
- 2010-02
- Primary completion
- 2010-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.